Your browser doesn't support javascript.
loading
Study of fingolimod, nitric oxide inhibitor, and P-glycoprotein inhibitor in modulating the P-glycoprotein expression via an endothelin-sphingolipid pathway in an animal model of pharmacoresistant epilepsy.
Garg, Nitika; Joshi, Rupa; Bhatia, Alka; Bansal, Seema; Chakrabarti, Amitava; Prakash, Ajay; Saikia, Biman; Modi, Manish; Medhi, Bikash.
Afiliação
  • Garg N; Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.
  • Joshi R; Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh; Department of Pharmacology, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be university), Mullana, Ambala, Haryana, India.
  • Bhatia A; Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.
  • Bansal S; Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh; Department of Pharmacology, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be university), Mullana, Ambala, Haryana, India.
  • Chakrabarti A; Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.
  • Prakash A; Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.
  • Saikia B; Department of Immunopathology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.
  • Modi M; Department of Neurology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.
  • Medhi B; Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.
Indian J Pharmacol ; 55(5): 307-314, 2023.
Article em En | MEDLINE | ID: mdl-37929409
ABSTRACT

BACKGROUND:

The overexpression of P-glycoprotein (P-gp) contributes to drug resistance in patients with epilepsy, and the change of P-gp expression located at the blood-brain barrier alienates the anti-seizure effects of P-gp substrates. Thus, the present study explored the effect of fingolimod (FTY720) acting through an endothelin-sphingolipid pathway on P-gp-induced pentylenetetrazol (PTZ)-kindled phenobarbital (PB)-resistant rats. MATERIALS AND

METHODS:

PTZ kindling (30 mg/kg; i.p.) and PB (40 mg/kg; orally) were used to develop an animal model of refractory epilepsy. The effect of Fingolimod on seizure score (Racine scale), plasma and brain levels of PB (high-performance liquid chromatography), and blood-brain barrier permeability (Evans blue dye) was determined. Further, Fingolimod's neuroprotective effect was determined by measuring the levels of various inflammatory cytokines, oxidative stress parameters, and neurotrophic factors in rat brain homogenate. The Fingolimod's effect on P-gp expression was estimated by reverse transcriptase-polymerase chain reaction and immunohistochemistry in rat brain. The H and E staining was done to determine the neuronal injury.

RESULTS:

Fingolimod significantly (P < 0.001) reduced the seizure score in a dose-dependent manner and alleviated the blood-brain barrier permeability. It decreased the P-gp expression, which further increased the brain PB concentration. Fingolimod significantly (P < 0.01) reduced oxidative stress as well as inflammation. Moreover, it attenuated the raised neuronal injury score in a resistant model of epilepsy.

CONCLUSION:

The modulation of the P-gp expression by Fingolimod improved drug delivery to the brain in an animal model of refractory epilepsy. Therefore, S1P signaling could serve as an additional therapeutic target to overcome refractoriness.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia Resistente a Medicamentos / Cloridrato de Fingolimode Limite: Animals / Humans Idioma: En Revista: Indian J Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Epilepsia Resistente a Medicamentos / Cloridrato de Fingolimode Limite: Animals / Humans Idioma: En Revista: Indian J Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia